search
Back to results

Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...

Primary Purpose

Hypertrophic Cardiomyopathy

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Paragon Pacemaker
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertrophic Cardiomyopathy focused on measuring Pacemaker, Pediatric, Obstructive HCM

Eligibility Criteria

5 Years - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA: DDD Pacemaker Therapy Children of either gender, aged 5 to 15 years. Presence of LV hypertrophy and LV outflow obstruction. EXCLUSION CRITERIA: DDD Pacemaker Therapy Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization. Chronic atrial fibrillation. Positive pregnancy test. INCLUSION CRITERIA: Cohort Study Children of either gender, 5 to 20 years (children greater than 15 years will be included if there is access to reliable previous catheterization data). Presence of LV hypertrophy and LV obstruction. EXCLUSION CRITERIA: Cohort Study Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization. Chronic atrial fibrillation. Positive pregnancy test.

Sites / Locations

  • National Institutes of Health Clinical Center, 9000 Rockville Pike

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 3, 1999
Last Updated
June 30, 2017
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00001396
Brief Title
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
Official Title
Obstructive Hypertrophic Cardiomyopathy (HCM) in Children: Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
July 23, 2008
Overall Recruitment Status
Completed
Study Start Date
October 6, 1993 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 23, 2008 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

5. Study Description

Brief Summary
Several studies have shown that specialized pacemaking devices (DDD pacing) can improve the symptoms associated with hypertrophic cardiomyopathy (HCM) in adults. In addition, studies have also shown that specialized pacemaking devices (DDD pacing) can improve conditions of HCM in children. However, growth of the body and organs, including the heart, is very rapid during childhood. Therefore the long-term effects of DDD pacing in children are unknown. The purpose of this study is to examine the growth rate and nutrition of children with HCM. Due to this heart condition and the restrictions that are often placed on the child's activity level, children with HCM may grow at a slower rat and may have a greater tendency to be overweight. Children participating in the study will have their growth rate and nutritional status measured before the study begins and throughout the course of the study. Findings in this research study will not directly benefit the patients participating in it. However, information gathered as a result of this study may lead to improvements in the management of children with HCM in the future.
Detailed Description
Several studies have shown that dual chamber (DDD) pacemaker therapy relieves LV outflow obstruction and improves symptoms in most adult patients with obstructive hypertrophic cardiomyopathy (HCM). It is however, uncertain whether DDD pacing will be efficacious in children with obstructive HCM, because of evolving cardiac morphology and increased LV hypertrophy and outflow obstruction associated with rapid body growth. We propose to monitor clinical progress, and cardiac morphologic and hemodynamic changes over several years following implantation of a DDD pacemaker in children who present with obstructive HCM between the ages of 5 to 15 years. Functional status, myocardial ischemia, arrhythmias, and LV outflow obstruction will be evaluated by exercise tests, echocardiography, thallium scintigraphy, Holter monitoring, electrophysiologic and cardiac catheterization studies. The results of pacemaker therapy will be compared with the findings in a cohort of young patients with obstructive HCM who elect not to be treated with DDD pacemaker.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertrophic Cardiomyopathy
Keywords
Pacemaker, Pediatric, Obstructive HCM

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Enrollment
100 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Paragon Pacemaker

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: DDD Pacemaker Therapy Children of either gender, aged 5 to 15 years. Presence of LV hypertrophy and LV outflow obstruction. EXCLUSION CRITERIA: DDD Pacemaker Therapy Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization. Chronic atrial fibrillation. Positive pregnancy test. INCLUSION CRITERIA: Cohort Study Children of either gender, 5 to 20 years (children greater than 15 years will be included if there is access to reliable previous catheterization data). Presence of LV hypertrophy and LV obstruction. EXCLUSION CRITERIA: Cohort Study Other systemic disease that prevent evaluation by echocardiography or cardiac catheterization. Chronic atrial fibrillation. Positive pregnancy test.
Facility Information:
Facility Name
National Institutes of Health Clinical Center, 9000 Rockville Pike
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
1350522
Citation
Fananapazir L, Cannon RO 3rd, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation. 1992 Jun;85(6):2149-61. doi: 10.1161/01.cir.85.6.2149.
Results Reference
background
PubMed Identifier
8624871
Citation
Slade AK, Sadoul N, Shapiro L, Chojnowska L, Simon JP, Saumarez RC, Dodinot B, Camm AJ, McKenna WJ, Aliot E. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996 Jan;75(1):44-9. doi: 10.1136/hrt.75.1.44.
Results Reference
background
PubMed Identifier
1510015
Citation
McAreavey D, Fananapazir L. Altered cardiac hemodynamic and electrical state in normal sinus rhythm after chronic dual-chamber pacing for relief of left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol. 1992 Sep 1;70(6):651-6. doi: 10.1016/0002-9149(92)90207-f.
Results Reference
background

Learn more about this trial

Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...

We'll reach out to this number within 24 hrs